Disease · MONDO_0010888

adenomyosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adenomyosis. Diseases, record MONDO_0010888. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010888

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adenomyosis; Open Targets
Open Targets ID: MONDO_0010888; Open Targets
Other names: adenomyosis of the uterus, adenomyosis of uterus, endometriosis (disease) of myometrium, endometriosis interna, endometriosis of myometrium, endometriosis of uterus, endometriosis, myometrium, myometrium endometriosis (disease), uterine adenomyosis, uterine corpus adenomyosis, uterus corpus adenomyosis; Open Targets
Disease Ontology: DOID:288; Disease Ontology
MeSH: D062788; MeSH
NCI Thesaurus: C6996; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 19 drugs, from ClinicalTrials.gov; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GONADORELIN	CHEMBL1007	Protein	Phase 3	ClinicalTrials.gov	4	4	2	Drugs and targets
GONADORELIN ACETATE	CHEMBL1200511	Protein	Phase 3	ClinicalTrials.gov	4	4	2	Drugs and targets
ESTRADIOL	CHEMBL135	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
NINTEDANIB	CHEMBL502835	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
MIFEPRISTONE	CHEMBL1276308	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
GOSERELIN	CHEMBL1201247	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVONORGESTREL	CHEMBL1389	Small molecule	Phase 2	ClinicalTrials.gov	4	4	3	Drugs and targets
EPELSIBAN	CHEMBL2037511	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
QUINAGOLIDE	CHEMBL2218861	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GNRHR	Gonadotropin-releasing hormone receptor	5	Gonadotropin-releasing hormone receptor agonist	Phase 3	https://conductscience.org/library/genes/2798	Drugs and targets
PGR	Progesterone receptor	5	Progesterone receptor agonist; Progesterone receptor antagonist; Progesterone receptor modulator	Phase 2/3	https://conductscience.org/library/genes/5241	Drugs and targets
DRD2	D(2) dopamine receptor	2	D2-like dopamine receptor agonist; Dopamine D2 receptor agonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
ESR1	Estrogen receptor	2	Estrogen receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/1588	Drugs and targets
DRD3	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 1	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 1	https://conductscience.org/library/genes/1815	Drugs and targets
FGFR1	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR2	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2263	Drugs and targets
FGFR3	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2261	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials21

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03749109	Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis	Phase 2	67	2022-09-07	Endometriosis	QUINAGOLIDE	Its record names the disease	ClinicalTrials.gov
NCT03778359	Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis		5,000		Endometriosis, Adenomyosis	DIENOGEST, LEUPROLIDE	Its record names the disease	ClinicalTrials.gov
NCT06913075	FET in Adenomyosis	Not applicable	700		Adenomyosis	GONADORELIN, GONADORELIN ACETATE, LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT07065539	GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients	Not applicable	432		Adenomyosis of Uterus, Frozen Embryo Transfer (FET)	GONADORELIN, GONADORELIN ACETATE, LETROZOLE	Its record names the disease	ClinicalTrials.gov
NCT07162961	Nintedanib for Improving Reproductive Outcomes in Adenomyosis	Phase 3	328		Adenomyosis of Uterus	NINTEDANIB	Its record names the disease	ClinicalTrials.gov
NCT06581679	Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer	Not applicable	184		Adenomyosis	TRIPTORELIN	Its record names the disease	ClinicalTrials.gov
NCT05151016	Long-term Use of Mifepristone in the Treatment of Adenomyosis	Early phase 1	140		Adenomyosis, Mifepristone	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT03520439	Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis	Phase 2/3	134		Adenomyosis	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT03890042	Dienogest for Treatment of Adenomyotic Uteri	Not applicable	100		Adenomyosis	DIENOGEST, ETHINYL ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT05153928	Management of Uterine Leiomyomata and Adenomyosis		100		Abnormal Uterine Bleeding	NORETHINDRONE ACETATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 21

See all 21 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Quinagolide 1080 µg vs Placebo: deaths from any cause	0 of 35	0 of 32	67	NCT03749109	Trial comparisons
Quinagolide 1080 µg vs Placebo: serious adverse events	1 of 35	0 of 32	67	NCT03749109	Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39274438	RESULT	1	PubMed
37822471	RESULT	1	PubMed
37149412	RESULT	1	PubMed
36549997	RESULT	1	PubMed
35123042	RESULT	1	PubMed
34961515	RESULT	1	PubMed
34587658	RESULT	1	PubMed
33590656	RESULT	1	PubMed
32767677	RESULT	1	PubMed
29845696	RESULT	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0010888

GET https://conductscience.org/api/diseases/v1/MONDO_0010888/trials?page=2

API reference For AI assistants